Collegium Pharmaceutical Inc (COLL)

Pretax margin

		Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Earnings before tax but after interest (EBT)	US$ in thousands	98,568	75,733	-28,847	-3,374	27,582
Revenue	US$ in thousands	631,449	566,767	463,933	276,868	310,016
Pretax margin		15.61%	13.36%	-6.22%	-1.22%	8.90%

December 31, 2024 calculation

Pretax margin = EBT ÷ Revenue
= $98,568K ÷ $631,449K
= 15.61%

The pretax margin of Collegium Pharmaceutical Inc has fluctuated over the years based on the provided data.

- As of December 31, 2020, the pretax margin stood at 8.90%, indicating that the company was able to generate a healthy profit before considering taxes.
- By December 31, 2021, the pretax margin decreased to -1.22%, signaling that the company may have incurred losses before tax expenses during that period.
- This negative trend continued into December 31, 2022, with a pretax margin of -6.22%, suggesting that Collegium Pharmaceutical Inc faced significant challenges in managing its operating expenses relative to its revenue.
- However, the company saw a significant turnaround by December 31, 2023, with a notable pretax margin of 13.36%, indicating improved profitability and efficiency in its operations.
- This positive momentum continued into December 31, 2024, where the pretax margin further increased to 15.61%, showcasing Collegium Pharmaceutical Inc's ability to generate higher profits before tax deductions.

Overall, the pretax margin of Collegium Pharmaceutical Inc has shown variability over the years, with a mixture of positive and negative performances. It is essential for the company to sustain or improve its pretax margin in order to ensure long-term financial health and stability.